This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Alliance Remove Pharmaceutical Remove Security Related Topics
Value Chain Due Diligence Competitive Landscape Innovation Globalization Security Technology Capital Marketing Business More Related Topics >
article thumbnail

Global Healthcare Industry – M&A and Capital Market Landscape Update

Evalueserve

DECEMBER 6, 2021

The following trends have resulted in an overall improvement in M&A sentiments in the industry vs 2020: Unprecedented levels of alliances in the R&D ecosystem as several major biopharma companies collaborated to effectively leverage their resources to stem innovation. Sponsor deals rebounded exceptionally.

Capital 98
Capital Globalization Biotech Marketing 98
article thumbnail

Weighing risk and reward with gen AI vendor selection

CIO

JANUARY 3, 2024

There’s bias in both the training data sets and in the results, and there are ethical concerns, runaway costs, integration challenges, model drift, lack of transparency, data security risks, plagiarism risks, and regulatory risks. In addition, for particularly sensitive business information and data, he expects to see even more security.

Alliance 821
Alliance Due Diligence Pharmaceutical Technology 821
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 17,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024